ACLX
Arcellx, Inc.
Price Chart
Latest Quote
$69.47
Current Price| Previous Close | $68.31 |
| Open | $67.71 |
| Day High | $69.98 |
| Day Low | $67.71 |
| Volume | 573,798 |
Stock Information
| Shares Outstanding | 57.82M |
| Total Debt | $51.79M |
| Cash Equivalents | $461.38M |
| Revenue | $35.90M |
| Net Income | $-217.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.02B |
| EPS (TTM) | $-3.93 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 17/42| Debt to Equity | 0.12 |
| Debt to Earnings | -0.51 |
| Current Ratio | 4.78 |
| Quick Ratio | 4.68 |
| Profit Margin | -99.46% |
| Return on Equity | -23.60% |
| Avg FCF Growth | 15.36% |
| FCF Yield | -2.41% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $69.47 | 573,798 |
| 2026-01-30 | $68.31 | 841,800 |
| 2026-01-29 | $68.26 | 483,100 |
| 2026-01-28 | $68.14 | 659,800 |
| 2026-01-27 | $68.51 | 1,094,200 |
| 2026-01-26 | $68.55 | 701,400 |
| 2026-01-23 | $67.70 | 828,600 |
| 2026-01-22 | $68.62 | 1,573,500 |
| 2026-01-21 | $68.87 | 1,242,400 |
| 2026-01-20 | $72.17 | 2,417,300 |
| 2026-01-16 | $68.94 | 573,600 |
| 2026-01-15 | $68.32 | 639,000 |
| 2026-01-14 | $69.86 | 854,400 |
| 2026-01-13 | $66.75 | 520,700 |
| 2026-01-12 | $64.87 | 557,800 |
| 2026-01-09 | $66.27 | 1,022,700 |
| 2026-01-08 | $64.31 | 1,210,800 |
| 2026-01-07 | $65.01 | 1,211,700 |
| 2026-01-06 | $62.06 | 823,500 |
| 2026-01-05 | $61.83 | 870,700 |
About Arcellx, Inc.
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
📰 Latest News
Arcellx Director Sells 6,000 Shares for $450,000
Motley Fool • 2026-02-01T03:10:04Z
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect
Insider Monkey • 2026-01-30T05:24:12Z
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
Zacks • 2026-01-21T14:40:03Z
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR‑T Program
Simply Wall St. • 2025-12-24T00:14:35Z
Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls
The Fly • 2025-12-22T14:47:26Z
Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More
24/7 Wall St. • 2025-12-22T13:12:30Z
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
Insider Monkey • 2025-12-11T12:44:22Z
Cancer Study Buoys These Small Biotechs
Barrons.com • 2025-12-09T20:31:00Z
Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans
Simply Wall St. • 2025-12-08T07:07:28Z
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
Insider Monkey • 2025-11-30T10:42:08Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $107,936,000 | $110,319,000 | $0 | $0 |
| Operating Revenue | $107,936,000 | $110,319,000 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $1,030,000 | $3,842,000 | $1,720,000 | $10,000 |
| Total Expenses | $245,507,000 | $200,199,000 | $191,259,000 | $65,018,000 |
| Net Non Operating Interest Income Expense | $32,292,000 | $19,853,000 | $2,580,000 | $49,000 |
| Interest Expense Non Operating | $1,030,000 | $3,842,000 | $1,720,000 | $10,000 |
| Operating Expense | $245,507,000 | $200,199,000 | $191,259,000 | $65,018,000 |
| General And Administrative Expense | $88,414,000 | $66,350,000 | $41,704,000 | $18,135,000 |
| Other Income Expense | - | - | - | $49,000 |
| Other Non Operating Income Expenses | - | - | - | $49,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Net Interest Income | $32,292,000 | $19,853,000 | $2,580,000 | $49,000 |
| Interest Income | $33,322,000 | $23,695,000 | $4,300,000 | $59,000 |
| Normalized Income | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Net Income From Continuing And Discontinued Operation | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Total Operating Income As Reported | $-137,571,000 | $-89,880,000 | $-191,259,000 | $-65,018,000 |
| Net Income Common Stockholders | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Net Income | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Net Income Including Noncontrolling Interests | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Net Income Continuous Operations | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Pretax Income | $-105,279,000 | $-70,027,000 | $-188,679,000 | $-64,969,000 |
| Interest Income Non Operating | $33,322,000 | $23,695,000 | $4,300,000 | $59,000 |
| Operating Income | $-137,571,000 | $-89,880,000 | $-191,259,000 | $-65,018,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.00 | $-1.47 | $-5.19 | $-1.94 |
| Basic EPS | $-2.00 | $-1.47 | $-5.19 | $-1.94 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-99,061,000 | $-64,145,000 | $-185,638,000 | $-63,918,000 |
| Reconciled Depreciation | $5,188,000 | $2,040,000 | $1,321,000 | $1,041,000 |
| EBITDA (Bullshit earnings) | $-99,061,000 | $-64,145,000 | $-185,638,000 | $-63,918,000 |
| EBIT | $-104,249,000 | $-66,185,000 | $-186,959,000 | $-64,959,000 |
| Diluted Average Shares | $53,566,153 | $48,061,450 | $36,355,758 | $33,543,534 |
| Basic Average Shares | $53,566,153 | $48,061,450 | $36,355,758 | $33,543,534 |
| Diluted NI Availto Com Stockholders | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Tax Provision | $2,069,000 | $663,000 | $0 | - |
| Research And Development | $157,093,000 | $133,849,000 | $149,555,000 | $46,883,000 |
| Selling General And Administration | $88,414,000 | $66,350,000 | $41,704,000 | $18,135,000 |
| Other Gand A | $88,414,000 | $66,350,000 | $41,704,000 | $18,135,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $454,792,000 | $485,380,000 | $204,954,000 | $-121,515,000 |
| Total Assets | $711,327,000 | $825,132,000 | $313,817,000 | $128,782,000 |
| Total Non Current Assets | $112,017,000 | $108,769,000 | $46,954,000 | $15,973,000 |
| Other Non Current Assets | $3,495,000 | $11,774,000 | $7,064,000 | $2,483,000 |
| Investmentin Financial Assets | $38,277,000 | $27,168,000 | $0 | - |
| Current Assets | $599,310,000 | $716,363,000 | $266,863,000 | $112,809,000 |
| Other Current Assets | $5,845,000 | $5,679,000 | $3,667,000 | $2,049,000 |
| Restricted Cash | $208,000 | $1,903,000 | $0 | - |
| Prepaid Assets | $5,882,000 | $6,764,000 | $8,361,000 | $6,143,000 |
| Cash Cash Equivalents And Short Term Investments | $587,375,000 | $702,017,000 | $254,835,000 | $104,617,000 |
| Cash And Cash Equivalents | $105,679,000 | $394,583,000 | $64,179,000 | $30,833,000 |
| Non Current Deferred Assets | - | - | $0 | $3,172,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $54,080,000 | $97,625,000 | $88,131,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $46,542,000 | $50,841,000 | $52,170,000 | $0 |
| Current Debt And Capital Lease Obligation | $7,538,000 | $46,784,000 | $35,961,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $256,535,000 | $339,752,000 | $108,863,000 | $250,297,000 |
| Total Non Current Liabilities Net Minority Interest | $131,130,000 | $221,514,000 | $52,170,000 | $235,452,000 |
| Other Non Current Liabilities | $8,593,000 | - | - | $178,000 |
| Non Current Deferred Liabilities | $75,995,000 | $170,673,000 | $0 | $1,895,000 |
| Current Liabilities | $125,405,000 | $118,238,000 | $56,693,000 | $14,845,000 |
| Other Current Liabilities | $8,531,000 | $8,214,000 | $3,131,000 | $1,973,000 |
| Current Deferred Liabilities | $59,056,000 | $50,533,000 | $0 | $183,000 |
| Payables And Accrued Expenses | $39,842,000 | $7,178,000 | $12,254,000 | $9,260,000 |
| Payables | $23,335,000 | $2,619,000 | $9,053,000 | $1,333,000 |
| Accounts Payable | $2,095,000 | $2,619,000 | $9,053,000 | $1,333,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $454,792,000 | $485,380,000 | $204,954,000 | $-121,515,000 |
| Total Equity Gross Minority Interest | $454,792,000 | $485,380,000 | $204,954,000 | $-121,515,000 |
| Stockholders Equity | $454,792,000 | $485,380,000 | $204,954,000 | $-121,515,000 |
| Gains Losses Not Affecting Retained Earnings | $848,000 | $547,000 | $-221,000 | $-20,000 |
| Other Equity Adjustments | $848,000 | $547,000 | $-221,000 | $-20,000 |
| Retained Earnings | $-496,828,000 | $-389,480,000 | $-318,790,000 | $-130,111,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $233,379,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $54,293,597 | $52,280,077 | $44,105,981 | $33,543,534 |
| Share Issued | $54,293,597 | $52,280,077 | $44,105,981 | $33,543,534 |
| Tangible Book Value | $454,792,000 | $485,380,000 | $204,954,000 | $-121,515,000 |
| Invested Capital | $454,792,000 | $485,380,000 | $204,954,000 | $-121,515,000 |
| Working Capital | $473,905,000 | $598,125,000 | $210,170,000 | $97,964,000 |
| Capital Lease Obligations | $54,080,000 | $97,625,000 | $88,131,000 | $0 |
| Total Capitalization | $454,792,000 | $485,380,000 | $204,954,000 | $-121,515,000 |
| Additional Paid In Capital | $950,719,000 | $874,261,000 | $523,921,000 | $8,615,000 |
| Capital Stock | $53,000 | $52,000 | $44,000 | $1,000 |
| Common Stock | $53,000 | $52,000 | $44,000 | $1,000 |
| Non Current Deferred Revenue | $75,995,000 | $170,673,000 | $0 | - |
| Long Term Capital Lease Obligation | $46,542,000 | $50,841,000 | $52,170,000 | $0 |
| Current Deferred Revenue | $59,056,000 | $50,533,000 | $0 | - |
| Current Capital Lease Obligation | $7,538,000 | $46,784,000 | $35,961,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,438,000 | $5,529,000 | $5,347,000 | $3,429,000 |
| Current Accrued Expenses | $16,507,000 | $4,559,000 | $3,201,000 | $7,927,000 |
| Dueto Related Parties Current | $21,240,000 | $0 | - | - |
| Investments And Advances | $38,277,000 | $27,168,000 | $0 | - |
| Available For Sale Securities | $38,277,000 | $27,168,000 | - | - |
| Net PPE | $70,245,000 | $69,827,000 | $39,890,000 | $10,318,000 |
| Accumulated Depreciation | $-9,444,000 | $-5,253,000 | $-3,461,000 | $-2,162,000 |
| Gross PPE | $79,689,000 | $75,080,000 | $43,351,000 | $12,480,000 |
| Leases | $38,373,000 | $27,153,000 | $2,399,000 | $2,355,000 |
| Construction In Progress | $200,000 | $7,792,000 | $1,700,000 | $142,000 |
| Other Properties | $40,052,000 | $39,315,000 | $39,011,000 | $9,829,000 |
| Machinery Furniture Equipment | $1,064,000 | $820,000 | $241,000 | $154,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $481,696,000 | $307,434,000 | $190,656,000 | $73,784,000 |
| Preferred Stock | - | - | $0 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-96,901,000 | $186,145,000 | $-101,580,000 | $-60,021,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-83,467,000 | $207,573,000 | $-99,303,000 | $-54,238,000 |
| Cash Flow From Continuing Operating Activities | $-83,467,000 | $207,573,000 | $-99,303,000 | $-54,238,000 |
| Operating Gains Losses | $-260,000 | $174,000 | $3,000 | $3,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-13,434,000 | $-21,428,000 | $-2,277,000 | $-5,783,000 |
| Investing Cash Flow | $-183,045,000 | $-154,512,000 | $-117,674,000 | $-79,976,000 |
| Cash Flow From Continuing Investing Activities | $-183,045,000 | $-154,512,000 | $-117,674,000 | $-79,976,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $0 | $299,706,000 | $259,833,000 | $119,118,000 |
| Financing Cash Flow | $-24,087,000 | $279,163,000 | $252,625,000 | $118,451,000 |
| Cash Flow From Continuing Financing Activities | $-24,087,000 | $279,163,000 | $252,625,000 | $118,451,000 |
| Net Common Stock Issuance | $0 | $299,706,000 | $259,833,000 | $-24,000 |
| Common Stock Issuance | $0 | $299,706,000 | $259,833,000 | $0 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-24,000 |
| Net Preferred Stock Issuance | - | $0 | $0 | $119,118,000 |
| Preferred Stock Issuance | - | $0 | $0 | $119,118,000 |
| Net Other Financing Charges | - | - | - | $-688,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-39,846,000 | $-29,392,000 | $-9,675,000 | $-387,000 |
| Income Tax Paid Supplemental Data | $1,635,000 | $212,000 | $0 | - |
| End Cash Position | $108,305,000 | $398,904,000 | $66,680,000 | $31,032,000 |
| Beginning Cash Position | $398,904,000 | $66,680,000 | $31,032,000 | $46,795,000 |
| Changes In Cash | $-290,599,000 | $332,224,000 | $35,648,000 | $-15,763,000 |
| Proceeds From Stock Option Exercised | $15,759,000 | $8,849,000 | $2,467,000 | $432,000 |
| Net Issuance Payments Of Debt | $-39,846,000 | $-29,392,000 | $-9,675,000 | $-387,000 |
| Net Long Term Debt Issuance | $-39,846,000 | $-29,392,000 | $-9,675,000 | $-387,000 |
| Long Term Debt Payments | $-39,846,000 | $-29,392,000 | $-9,675,000 | $-387,000 |
| Net Investment Purchase And Sale | $-169,611,000 | $-133,084,000 | $-115,397,000 | $-74,193,000 |
| Sale Of Investment | $427,700,000 | $309,345,000 | $158,340,000 | $0 |
| Purchase Of Investment | $-597,311,000 | $-442,429,000 | $-273,737,000 | $-74,193,000 |
| Net PPE Purchase And Sale | $-13,434,000 | $-21,428,000 | $-2,277,000 | $-5,783,000 |
| Purchase Of PPE | $-13,434,000 | $-21,428,000 | $-2,277,000 | $-5,783,000 |
| Change In Working Capital | $-30,778,000 | $225,427,000 | $4,452,000 | $2,723,000 |
| Change In Other Working Capital | $-86,154,000 | $221,206,000 | - | $44,000 |
| Change In Other Current Liabilities | $4,826,000 | $13,461,000 | $3,123,000 | $0 |
| Change In Payables And Accrued Expense | $41,939,000 | $-881,000 | $7,024,000 | $8,738,000 |
| Change In Accrued Expense | $42,009,000 | $5,593,000 | $-395,000 | $7,764,000 |
| Change In Payable | $-70,000 | $-6,474,000 | $7,419,000 | $974,000 |
| Change In Account Payable | $-70,000 | $-6,474,000 | $7,419,000 | $974,000 |
| Change In Prepaid Assets | $8,611,000 | $-8,359,000 | $-5,695,000 | $-6,059,000 |
| Other Non Cash Items | $4,104,000 | $19,881,000 | $64,181,000 | - |
| Stock Based Compensation | $61,086,000 | $41,789,000 | $21,544,000 | $6,754,000 |
| Amortization Of Securities | $-15,459,000 | $-11,048,000 | $-2,125,000 | $210,000 |
| Depreciation Amortization Depletion | $5,188,000 | $2,040,000 | $1,321,000 | $1,041,000 |
| Depreciation And Amortization | $5,188,000 | $2,040,000 | $1,321,000 | $1,041,000 |
| Gain Loss On Sale Of PPE | $-260,000 | $174,000 | $3,000 | $3,000 |
| Net Income From Continuing Operations | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 |
| Common Stock Payments | - | $0 | $0 | $-24,000 |